Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Name
s41591-020-1070-6.pdf
Size
8.34 MB
Format
Adobe PDF
Checksum (MD5)
324143a20f1c581e0599eae41360b5d6
Author(s)
Tostanoski, Lisa H.
Wegmann, Frank
Martinot, Amanda J.
Loos, Carolin
McMahan, Katherine
Mercado, Noe B.
Yu, Jingyou
Chan, Chi N.
Bondoc, Stephen
Starke, Carly E.
Date Issued
September 2020
Journal
Nature Medicine
Citation
Tostanoski, Lisa H. et al. "Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters." Nature Medicine (September 2020): doi.org/10.1038/s41591-020-1070-6 © 2020 Springer Nature
Version
Final published version
Abstract
Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death. Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters and nonhuman primates have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates. Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41591-020-1070-6
